نتایج جستجو برای: concentrated fviii

تعداد نتایج: 43809  

Journal: :Blood 2013
Samantha C Gouw H Marijke van den Berg Kathelijn Fischer Günter Auerswald Manuel Carcao Elizabeth Chalmers Hervé Chambost Karin Kurnik Ri Liesner Pia Petrini Helen Platokouki Carmen Altisent Johannes Oldenburg Beatrice Nolan Rosario Pérez Garrido M Elisa Mancuso Anne Rafowicz Mike Williams Niels Clausen Rutger A Middelburg Rolf Ljung Johanna G van der Bom

The objective of this study was to examine the association of the intensity of treatment, ranging from high-dose intensive factor VIII (FVIII) treatment to prophylactic treatment, with the inhibitor incidence among previously untreated patients with severe hemophilia A. This cohort study aimed to include consecutive patients with a FVIII activity < 0.01 IU/mL, born between 2000 and 2010, and ob...

Journal: :Proceedings of the National Academy of Sciences of the United States of America 2007
Suryasarathi Dasgupta Ana-Maria Navarrete Jagadeesh Bayry Sandrine Delignat Bharath Wootla Sébastien André Olivier Christophe Michelina Nascimbeni Marc Jacquemin Luisa Martinez-Pomares Teunis B H Geijtenbeek Arnaud Moris Jean-Marie Saint-Remy Michel D Kazatchkine Srinivas V Kaveri Sébastien Lacroix-Desmazes

Several therapeutic self-proteins elicit immune responses when administered to patients. Such adverse immune responses reduce drug efficacy. To induce an immune response, a protein must interact with different immune cells, including antigen-presenting cells, T cells, and B cells. Each cell type recognizes distinct immunogenic patterns on antigens. Mannose-terminating glycans have been identifi...

2009
Maartje van den Biggelaar Alexander B. Meijer Jan Voorberg Koen Mertens

Weibel-Palade bodies (WPBs) are the endothelial storage organelles that are formed upon von Willebrand factor (VWF) expression. Apart from VWF, WPBs contain a variety of hemostatic and inflammatory proteins. Some of these are thought to be targeted to WPBs by directly interacting with VWF in the secretory pathway. Previous studies have demonstrated that coexpression of factor VIII (FVIII) with ...

Journal: :Thrombosis and haemostasis 2006
A Yaël Nossent Jeroen C J Eikenboom Hans L Vos Egbert Bakker Bea C Tanis Carine J M Doggen Rogier M Bertina Frits R Rosendaal

Levels of factor VIII (FVIII) are associated with the risk of venous thrombosis. The FVIII variation D1241E has been reported to be associated with decreased levels of FVIII. Our objective was to study whether D1241E is associated with levels of FVIII and the risk of venous thrombosis and whether this association is caused by D1241E or another linked variation. We analyzed the association of th...

Journal: :Blood 2005
John R Ohlfest Joel L Frandsen Sabine Fritz Paul D Lobitz Scott G Perkinson Karl J Clark Gary Nelsestuen Nigel S Key R Scott McIvor Perry B Hackett David A Largaespada

Hemophilia A is a lead candidate for treatment by gene therapy because small increments in the missing secreted protein product, coagulation factor VIII (FVIII), would result in substantial clinical amelioration. Clinically relevant therapy might be achieved by stably delivering a human FVIII cDNA to correct the bleeding disorder. We used the Sleeping Beauty (SB) transposon, delivered as naked ...

Journal: :Journal of thrombosis and haemostasis : JTH 2012
S R Selvaraj A N Scheller H Z Miao R J Kaufman Steven W Pipe

BACKGROUND Heterologous expression of factor VIII (FVIII) is about two to three orders of magnitude lower than similarly sized proteins. Bioengineering strategies aimed at different structural and biochemical attributes of FVIII have been successful in enhancing its expression levels. OBJECTIVE Disulfide bonds are vital to the proper folding, secretion and stability of most secretory proteins...

2004
Jean Guy G. Gilles Sabrina C. Grailly Marc De Maeyer Marc G. Jacquemin Luc P. VanderElst Jean-Marie R. Saint-Remy

Factor VIII (FVIII) administration elicits specific inhibitory antibodies (Abs) in about 25% of patients with hemophilia A. The majority of such Abs reacts with FVIII C2 domain. mAbBO2C11 is a high-affinity human monoclonal antibody (mAb) directed toward the C2 domain, which is representative of a major class of human FVIII inhibitors. Anti-idiotypic Abs were raised to mAbBO2C11 to establish th...

Journal: :Blood 2004
Christina Hausl Rafi U Ahmad Hans Peter Schwarz Eva M Muchitsch Peter L Turecek Friedrich Dorner Birgit M Reipert

Memory B cells are responsible for the rapidly emerging antibody response after antigen reexposure. The signals required for the restimulation of memory B cells have not been fully explained. We used a murine model of anti-factor VIII (FVIII) antibody responses in hemophilia A to study the requirements for the restimulation of FVIII-specific memory B cells and their differentiation into anti-FV...

Journal: :Blood 2000
R T Barrow J F Healey D Gailani D Scandella P Lollar

Factor VIII (fVIII) circulates as a heavy chain/light chain (A1-A2-B/ap-A3-C1-C2) heterodimer. The 41-residue light chain activation peptide, ap, is cleaved from fVIII during proteolytic activation by thrombin or factor Xa. We constructed 7 active recombinant hybrid B-domainless human/porcine fVIII molecules that contained combinations of porcine sequence replacements within the A2, ap-A3, and ...

Journal: :Haematologica 2007
Sandrine Delignat Suryasarathi Dasgupta Sébastien André Ana-Maria Navarrete Srinivas V Kaveri Jagadeesh Bayry Marie-Hélène André Sami Chtourou Zéra Tellier Sébastien Lacroix-Desmazes

Von Willebrand factor (VWF) has been proposed to reduce the immunogenicity of therapeutic factor VIII (FVIII) in patients with hemophilia A. Using FVIII-deficient mice, we compared the immunogenicity of different preparations of plasma-derived (pd) and recombinant (r) FVIII. Treatment of mice with pdFVIII induced significantly lower titers of FVIII inhibitors, as measured by ELISA and in vitro ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید